For years, low uptake of guideline-directed therapy in heart failure has been blamed on access barriers—formulary limits, prior authorizations, step edits and patient costs. The assumption: fix access, and use will rise. But the access landscape has evolved. Explore why closing the GDMT gap now requires a new strategy in 2026.